From the event website:
“The World ADC Summit is the first and only meeting that is completely focussed on driving forward the development of Antibody-Drug Conjugates.
Building on last year’s hugely successful sell-out program, attend this meeting to address the challenges you are facing in R&D, clinical development, regulatory requirements, characterization and antibody processing. Download the agenda here.
And this year we’ve worked with our ADC Advisory Board: Paul Polakis (Genentech), John Lambert (ImmunoGen), Hans Peter Gerber (Pfizer), Sanjeev Gangwar, Dennis Benjamin (Seattle Genetics) and Peter Senter (Seattle Genetics) to bring you the most innovative and valuable program yet!
Register your place today to:
Get the latest clinical updates on T-DM1, SGN-35, CDX-11 and more
Discover the approaches to attaining favorable PK profiles
Find out the advances in linker technology, payload chemistry to optimize conjugate design earlier in development
Understand the latest thinking on mechanisms of drug-resistance
Be equipped with the regulatory guidance you need to successfully navigate the development process
Gain an insight into Roche’s conjugated bispecific platform
Overcome challenges in the characterization and process development of ADCs
Determine what tox, safety and efficacy you need to include in your IND package
And much more!”